IP Library Granted Patent US 10,800,843
Granted Patent B2
US 10,800,843 · App. 15/748,111 · Granted Oct 13, 2020

Beta klotho-binding proteins

Inventors: Kalyani Mondal (San Mateo, CA); Betty Chan Li (Millbrae, CA); Yu Chen (Foster City, CA); Taruna Arora (Palo Alto, CA); Hugo Matern (San Mateo, CA); Wenyan Shen (Redwood City, CA)
Assignee: NGM Biopharmaceuticals, Inc.
C07K16/28A61K39/001132A61K2039/505C07K2317/24C07K2317/52C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,800,843
App. No.
15/748,111
Granted
Oct 13, 2020
Kind
B2
Abstract

The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Claims (15)

1. An antibody or fragment thereof that binds human beta-klotho, which comprises

a heavy chain variable region comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, and a light chain variable region comprising a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6.

2. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:26 and the light chain variable region has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:27.

3. The antibody or fragment thereof of claim 1 , which is a monoclonal antibody.

4. The antibody or fragment thereof of claim 1 , which is a humanized antibody.

5. The antibody or fragment thereof of claim 1 , wherein the fragment is a Fab, Fab′, F(ab′) 2 , Fv, scFv, (scFv) 2 , single chain antibody, dual variable region antibody, or linear antibody.

6. A pharmaceutical composition which comprises the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

7. A method of activating a beta-klotho/FGF receptor complex in a cell, wherein the method comprises contacting the cell with the antibody or fragment thereof of claim 1 .

8. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:26 and the light chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:27.

9. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:26 and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:27.

10. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NOs:56-78.

11. The antibody or fragment thereof of claim 1 , wherein the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NOs:80-90, 124, 132, 134, 137, or 146.

12. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region comprises one of the amino acid sequences set forth in SEQ ID NOs:56-78 and the light chain variable region comprises one of the amino acid sequences set forth in SEQ ID NOs:80-90, 124, 132, 134, 137, or 146.

13. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:69 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:134.

14. The antibody or fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:70 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:137.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: ARORA, TARUNA
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 047908/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2018
From: MATERN, HUGO
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 047396/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: CHEN, YU
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 047086/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: MONDAL, KALYANI; LI, BETTY CHAN; SHEN, WENYAN
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 046930/0496 →
Continuity (2)
Provisional Application 62198664 · Jul 29, 2015
Related Publication 20190338046A1 · Nov 7, 2019
Cited By (1)
US 12,378,312